The EMA anticipates that the ability to access scientific advice will foster innovation among medical device manufacturers.

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Flu season has hit Poland hard, straining the country’s healthcare system. In response, Health Minister Izabela Leszczyna has ...

The European Medicines Agency (EMA) says its safety committee has begun a review into reports of an association between use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and a ...

AMSTERDAM, Jan 27 (Reuters) - The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization ...